7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,855.00

+579.93

+0.75%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NSE - Delayed Quote INR

Biocon Limited (BIOCON.NS)

351.80 -0.10 (-0.03%)

At close: October 30 at 3:28:19 PM GMT+5:30

Loading Chart for BIOCON.NS

Chart Range Bar

Interval:

In partnership with ChartIQ

Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ...

Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ...

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and ...

Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and ...

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach

Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump On Margin Focus And Peer Valuation Cues

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump On Margin Focus And Peer Valuation Cues

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions

How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump As Analysts Weigh Execution And Earnings Visibility

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump As Analysts Weigh Execution And Earnings Visibility

3 India Pharma Exporter Stocks Facing Fresh US Tariff Pressure

3 India Pharma Exporter Stocks Facing Fresh US Tariff Pressure

Mobilize your Website

View Site in Mobile | Classic

Share by: